- Home
- SWIN vs APRE Comparison
SWIN vs APRE Comparison
Compare SWIN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- APRE
- Stock Information
- Founded
- SWIN 2017
- APRE 2006
- Country
- SWIN Hong Kong
- APRE United States
- Employees
- SWIN N/A
- APRE N/A
- Industry
- SWIN
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWIN
- APRE Health Care
- Exchange
- SWIN Nasdaq
- APRE Nasdaq
- Market Cap
- SWIN 24.9M
- APRE 21.2M
- IPO Year
- SWIN 2023
- APRE 2019
- Fundamental
- Price
- SWIN $1.29
- APRE $2.62
- Analyst Decision
- SWIN
- APRE Strong Buy
- Analyst Count
- SWIN 0
- APRE 2
- Target Price
- SWIN N/A
- APRE $15.50
- AVG Volume (30 Days)
- SWIN 85.6K
- APRE 35.9K
- Earning Date
- SWIN 03-04-2025
- APRE 03-25-2025
- Dividend Yield
- SWIN N/A
- APRE N/A
- EPS Growth
- SWIN N/A
- APRE N/A
- EPS
- SWIN N/A
- APRE N/A
- Revenue
- SWIN $2,419,000.00
- APRE $1,310,839.00
- Revenue This Year
- SWIN N/A
- APRE $134.21
- Revenue Next Year
- SWIN $61.68
- APRE N/A
- P/E Ratio
- SWIN N/A
- APRE N/A
- Revenue Growth
- SWIN N/A
- APRE 130.31
- 52 Week Low
- SWIN $1.16
- APRE $2.15
- 52 Week High
- SWIN $72.55
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- SWIN 37.31
- APRE 30.05
- Support Level
- SWIN $1.16
- APRE $2.59
- Resistance Level
- SWIN $1.56
- APRE $3.72
- Average True Range (ATR)
- SWIN 0.14
- APRE 0.35
- MACD
- SWIN -0.01
- APRE -0.13
- Stochastic Oscillator
- SWIN 28.26
- APRE 1.41
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.